GI & Endoscopy

2021 will be a banner year for private equity investment in the gastroenterology space, and it's already kicked off. 

Here are four updates from GI companies and practices from the past week:

Patients with a family history of colorectal cancer that had a negative screening colonoscopy may be able to wait 10 years for their next exam, according to a study submitted to 2020 Digestive Disease Week, Gastroenterology and Endoscopy News reported…

Dallas-based GI Alliance made the first deals of 2021, partnering with Cleburne (Texas) Endoscopy Center, Oak Lawn, Ill.-based GI Associates of Chicago and Dallas-based Digestive Health Associates of Texas, the platform announced Jan. 5 and Jan. 6.

Sebela Pharmaceuticals launched its pill-based colonoscopy preparation, Sutab, in the U.S., the pharmaceutical company announced Jan. 5.

Memphis, Tenn.-based One GI made a pair of post-formation deals, partnering with Oxford, Miss.-based Gastroenterology Associates and Nashville, Tenn.-based Associates in Gastroenterology in separate deals. 

Leandro Feo, MD, joined Tenet Florida Physician Services to open an office in Boca Raton, according to South Florida Hospital News and Healthcare Report.

Here are the most-read GI stories from Dec. 28 to Jan. 1.

Micro-Tech Endoscopy and Interscope have partnered to collaborate and distribute the EndoRoter System for interventional gastroenterology, according to a Dec. 30 news release.

  The year was looking bright for Exact Sciences. The company planned to build on its 2019 acquisition of Genomic Health to create a multifaceted diagnostic testing company in 2020, but COVID-19-related disruptions altered the plan for the year.